Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1

Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia

(2016) Gloria Ravegnini et al.   Expert Opinion on Drug Metabolism & Toxicology

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters

(2016) Y Ma et al.   PHARMACOGENOMICS JOURNAL

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

(2015) Stefan Wolking et al.   CLINICAL PHARMACOKINETICS

SLC transporters as therapeutic targets: emerging opportunities

(2015) Lawrence Lin et al.   NATURE REVIEWS DRUG DISCOVERY

Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells

(2014) Petr Kosztyu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

(2014) Sophie Postel-Vinay et al.   EUROPEAN JOURNAL OF CANCER

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

(2014) A Di Paolo et al.   PHARMACOGENOMICS JOURNAL

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity

(2013) Daniel L Hertz et al.   JOURNAL OF HUMAN GENETICS

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome

(2013) S Bouchet et al.   LEUKEMIA

PharmGKB summary

(2013) Ugur Hodoglugil et al.   Pharmacogenetics and Genomics

The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

(2012) Wing L. Ho et al.   ACTA OPHTHALMOLOGICA

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

(2012) A. Giannoudis et al.   BLOOD

Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?

(2012) Antonio Rossi et al.   CANCER TREATMENT REVIEWS

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

(2012) S. Angelini et al.   HAEMATOLOGICA

C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients

(2012) Jing Gao et al.   MEDICAL ONCOLOGY

Pharmacogenetics ofEGFRin lung cancer: perspectives and clinical applications

(2012) Clara Mayo et al.   PHARMACOGENOMICS

Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy

(2012) Sabrina Angelini et al.   PHARMACOLOGICAL RESEARCH

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

(2011) Sophie Postel-Vinay et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management

(2010) Pascal Wolter et al.   ACTA ONCOLOGICA

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia

(2008) Richard E. Clark et al.   LEUKEMIA & LYMPHOMA